Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
To assess the efficacy and safety of orally administered hydroxyurea in the treatment of
 painful crises in patients with sickle cell anemia.
BACKGROUND:

 In spite of the fact that advances have been made in the management or prevention of some of
 the complications of sickle cell disease, the management of the most common complication--the
 painful crisis--is still unsatisfactory, and appropriate methods for its prevention are
 unknown. The morbidity associated with a painful crisis is much more than the suffering from
 pain alone. The interference with a normal lifestyle, the resulting obstacles to obtaining an
 education and holding a job, the risk of narcotics addiction, the cost of multiple
 hospitalizations, and the financial impact on the family and the individual must all be
 considered.

 Evidence from the Cooperative Study of Sickle Cell Disease (CSSCD) study showed that there is
 an association between multiple pain events and early death in young adults. If this
 association is true, then MSH has the potential to not only reduce morbidity but mortality as
 well. The CSSCD study has shown that over 50 percent of patients with sickle cell disease
 have at least one crisis per year, and a considerable number have more. These episodes are
 believed to occur as a result of hemoglobin S within the red cells leading to rigid,
 non-deformable cells which can no longer traverse the microvasculature and as a result
 produce obstruction with consequent pain, ischemia, and tissue necrosis.

 Previous approaches to the therapy of this group of disorders have included: attempts to
 modify the hemoglobin molecule so as to prevent polymerization; the use of vasoreactive
 drugs; and increasing red cell volume. All of these attempts have been abandoned either
 because of their inefficacy, toxicity, or impracticality. Chronic exchange transfusion
 programs have been of limited usefulness because of high rates of isoimmunization, iron
 overload, and risk of transmission of hepatitis and retroviral disease.

 The rationale for the present study draws its substance from the observation that patients
 with higher levels of fetal hemoglobin (Hb F) (particularly the Saudi Arabian group), and
 infants who also have high Hb F levels have fewer crises. Several myelosuppressive drugs,
 such as 5-azacytidine and hydroxyurea, have been shown to increase Hb F production. The work
 with 5-azacytidine has had to be abandoned because of the known risk of malignancy.

 Preliminary studies by the investigators and others have shown convincingly that Hb F levels
 can be increased by administering hydroxyurea to patients over a several month period without
 producing dangerous levels of myelosuppression. The patients have also had a rise in their
 red cell life span and hematocrit. Further, it has been reported that these patients had a
 dramatic decrease in crisis frequency. This agent is readily available to all physicians, and
 there is evidence that it is being used without adequate justification and, possibly, without
 adequate monitoring. The timing of this study is therefore critical to ensure that an
 adequate answer to the question of efficacy is obtained and the risk of inappropriate use
 minimized.

 DESIGN NARRATIVE:

 Phase I has concluded. Phase II, also concluded, was a randomized, double-blind,
 placebo-controlled trial. Patients in the Phase II trial were recruited from 21 clinics and
 randomized to receive hydroxyurea or placebo. The hydroxyurea was gradually increased from an
 initial dose of 15 mg/kg to the maximal level tolerated by each patient in order to maximize
 red blood cell hemoglobin F(Hb F) content without undue marrow suppression. Changes in Hb F
 production were monitored in each of the two groups by a variety of laboratory tests. The
 primary endpoint was a comparison of crisis rates in the treated and control groups. Painful
 crises were defined as pain lasting longer than four hours, requiring parenteral narcotics
 for relief, including chest syndrome but excluding ankle ulcer pain. Secondary endpoints
 included changes in pain severity and duration, psychosocial status, complications of the
 disease, and reasons for non-compliance with either regimen. Patients were followed for two
 to three years depending on when they entered the study. Because of the mutagenic nature of
 hydroxyurea, the use of contraception was a requirement of admission to the study.

 The trial was stopped early, on January 14, 1995, instead of in May 1995. The Data and Safety
 Monitoring Board determined that daily doses of hydroxyurea reduced the frequency of painful
 episodes and hospital admissions for those crises by about 50 percent.

 Beginning in 1996, a five year follow-up of the adult patients in MSH was initiated. The
 purpose was to ascertain the long-term effects of hydroxyurea in this patient population.
 Patients were followed annually to determine health status, quality of life, incidence of
 malignancies, and birth defects in their offspring. In addition, mortality rates were
 determined so that a comparison could be made between this cohort and the mortality data from
 the Cooperative Study of Sickle Cell Disease (CSSCD) adult cohort and the normal
 African-American population mortality data. The follow-up was conducted in three phases.
 Phase I or the Planning Phase in which the final protocol was developed, lasted three months.
 Phase II, patient entry between March 1996 and June 1996 and patient follow-up, extended from
 the fourth to the 48th month. Phase III, patient exit and data analysis, were carried out
 during the final nine months of the study.

 The DSMB stopped MSH Phase III early because the study showed that hydroxyurea substantially
 reduced the frequency of vaso-occlusive (painful) crises.
Men and women, ages 18 to 50, who had at least three emergency room visits or
 hospitalizations for sickle cell anemia during the year prior to recruitment. Patients with
 greater than 20 crises per year were included. A total of 295 patients had Hb ss and four
 had Hb SB thalassemia.